Efficacy, safety, and tolerability of oral Cebranopadol versus morphine sulphate PR in subjects with chronic moderate to severe pain related to cancer

Trial Profile

Efficacy, safety, and tolerability of oral Cebranopadol versus morphine sulphate PR in subjects with chronic moderate to severe pain related to cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Cebranopadol (Primary) ; Morphine
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Acronyms CORAL
  • Sponsors Grunenthal
  • Most Recent Events

    • 30 Sep 2016 Interim results (n=126) presented at the 16th World Congress on Pain
    • 30 Sep 2016 According to Grunenthal's Media Release, study was stopped because of strategic reasons and results from this study will be presented at the IASP conference in 2016.
    • 30 Sep 2016 According to Grunenthal's Media Release, Primary endpoint has been met. (Average amount of daily rescue medication at the end of the maintenance period.)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top